• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

快速建立一个登记系统以加速新冠疫苗临床试验。

Rapid development of a registry to accelerate COVID-19 vaccine clinical trials.

作者信息

Abernethy Neil F, McCloskey Kylie, Trahey Meg, Rinn Laurie, Broder Gail, Andrasik Michele, Laborde Rebecca, McGhan Daniel, Spendolini Scott, Marimuthu Senthil, Kanzmeier Adam, Hanes Jayson, Kublin James G

机构信息

Biomedical Informatics and Medical Education, University of Washington, Seattle, WA, USA.

HIV Vaccine Trials Network (HVTN), COVID-19 Prevention Network (CoVPN), Fred Hutchinson Cancer Center, Seattle, WA, USA.

出版信息

NPJ Digit Med. 2025 May 6;8(1):251. doi: 10.1038/s41746-025-01666-3.

DOI:10.1038/s41746-025-01666-3
PMID:40328984
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12056171/
Abstract

Response to the SARS-Cov-2 pandemic required the unprecedented, rapid activation of the COVID-19 Prevention Network (CoVPN) representing hundreds of sites conducting vaccine clinical trials. The CoVPN Volunteer Screening Registry (VSR) collected participant information, distributed qualified candidates across sites, and monitored enrollment progress. The system consisted of three web-based interfaces. The Volunteer Questionnaire flowed into a secure database. The Site Portal supported volunteer selection, analytics, and enrollment. The Administrative Portal enabled dynamic analytic reports by geography, clinical trial, and site, including volunteering rates over time. The VSR collected over 650,000 volunteers, serving a key role in the recruitment of diverse participants for multiple Phase 3 clinical trials. Over 47% of the 166,729 volunteers selected for screening represented prioritized groups. The success of the VSR demonstrates how digital tools can be rapidly yet safely integrated into an accelerated clinical trial setting. We summarize the development of the system and lessons learned for pandemic preparedness.

摘要

应对SARS-CoV-2大流行需要前所未有的迅速启动代表数百个进行疫苗临床试验地点的COVID-19预防网络(CoVPN)。CoVPN志愿者筛选登记处(VSR)收集参与者信息,在各地点分配合格候选人,并监测入组进度。该系统由三个基于网络的界面组成。志愿者问卷流入一个安全数据库。站点门户支持志愿者选择、分析和入组。管理门户可生成按地理区域、临床试验和站点划分的动态分析报告,包括随时间变化的志愿服务率。VSR收集了超过650,000名志愿者,在为多项3期临床试验招募不同参与者方面发挥了关键作用。在被选中进行筛选的166,729名志愿者中,超过47%代表优先群体。VSR的成功展示了数字工具如何能够快速且安全地融入加速的临床试验环境。我们总结了该系统的开发情况以及为大流行防范吸取的经验教训。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc6b/12056171/6085c6ee5334/41746_2025_1666_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc6b/12056171/2f195de24fc7/41746_2025_1666_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc6b/12056171/35ce6d913719/41746_2025_1666_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc6b/12056171/0a0244638525/41746_2025_1666_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc6b/12056171/f2e4ed3f11d8/41746_2025_1666_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc6b/12056171/6085c6ee5334/41746_2025_1666_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc6b/12056171/2f195de24fc7/41746_2025_1666_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc6b/12056171/35ce6d913719/41746_2025_1666_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc6b/12056171/0a0244638525/41746_2025_1666_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc6b/12056171/f2e4ed3f11d8/41746_2025_1666_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc6b/12056171/6085c6ee5334/41746_2025_1666_Fig5_HTML.jpg

相似文献

1
Rapid development of a registry to accelerate COVID-19 vaccine clinical trials.快速建立一个登记系统以加速新冠疫苗临床试验。
NPJ Digit Med. 2025 May 6;8(1):251. doi: 10.1038/s41746-025-01666-3.
2
Rapid Development of a Registry to Accelerate COVID-19 Vaccine Clinical Trials.为加速新冠疫苗临床试验而迅速建立登记系统
Res Sq. 2024 Jun 10:rs.3.rs-4397271. doi: 10.21203/rs.3.rs-4397271/v1.
3
VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment.VACCELERATE 志愿者注册中心:一个旨在促进临床试验入组的欧洲研究参与者数据库。
Vaccine. 2022 Jul 29;40(31):4090-4097. doi: 10.1016/j.vaccine.2022.05.022. Epub 2022 Jun 2.
4
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials.快速开发综合网络基础设施以开展 3 期 COVID-19 疫苗试验。
JAMA Netw Open. 2023 Jan 3;6(1):e2251974. doi: 10.1001/jamanetworkopen.2022.51974.
5
Increasing Black, Indigenous and People of Color participation in clinical trials through community engagement and recruitment goal establishment.通过社区参与和设定招募目标来增加黑人和原住民以及有色人种参与临床试验的比例。
PLoS One. 2021 Oct 19;16(10):e0258858. doi: 10.1371/journal.pone.0258858. eCollection 2021.
6
Enhancing Public Health Communication Regarding Vaccine Trials: Design and Development of the Pan-European VACCELERATE Toolkit.增强疫苗试验的公众健康传播:泛欧 VACCELERATE 工具包的设计与开发。
JMIR Public Health Surveill. 2023 Apr 3;9:e44491. doi: 10.2196/44491.
7
Perspectives of European Patient Advocacy Groups on Volunteer Registries and Vaccine Trials: VACCELERATE Survey Study.欧洲患者倡导团体对志愿者注册和疫苗试验的看法:VACCELERATE 调查研究。
JMIR Public Health Surveill. 2024 Apr 4;10:e47241. doi: 10.2196/47241.
8
Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.在普通人群中进行 SARS-CoV-2 监测的四种不同策略的有效性和成本效益(CoV-Surv 研究):一项关于集群随机、双因素对照试验的研究方案的结构化总结。
Trials. 2021 Jan 8;22(1):39. doi: 10.1186/s13063-020-04982-z.
9
VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe.VACCELERATE 站点网络:欧洲临床研究能力的实时定义。
Vaccine. 2023 Jun 13;41(26):3915-3922. doi: 10.1016/j.vaccine.2023.05.006. Epub 2023 May 18.
10
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗(灭活,Vero 细胞)有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.

本文引用的文献

1
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials.快速开发综合网络基础设施以开展 3 期 COVID-19 疫苗试验。
JAMA Netw Open. 2023 Jan 3;6(1):e2251974. doi: 10.1001/jamanetworkopen.2022.51974.
2
VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment.VACCELERATE 志愿者注册中心:一个旨在促进临床试验入组的欧洲研究参与者数据库。
Vaccine. 2022 Jul 29;40(31):4090-4097. doi: 10.1016/j.vaccine.2022.05.022. Epub 2022 Jun 2.
3
Seek COVER: using a disease proxy to rapidly develop and validate a personalized risk calculator for COVID-19 outcomes in an international network.
寻找替代指标:利用疾病替代指标在国际网络中快速开发和验证针对 COVID-19 结局的个体化风险计算器。
BMC Med Res Methodol. 2022 Jan 30;22(1):35. doi: 10.1186/s12874-022-01505-z.
4
Transmission of SARS-CoV-2 into and within immigrant households: nationwide registry study from Norway.严重急性呼吸综合征冠状病毒2在移民家庭中的传入和传播:挪威的全国登记研究
J Epidemiol Community Health. 2021 Dec 20. doi: 10.1136/jech-2021-217856.
5
Increasing Black, Indigenous and People of Color participation in clinical trials through community engagement and recruitment goal establishment.通过社区参与和设定招募目标来增加黑人和原住民以及有色人种参与临床试验的比例。
PLoS One. 2021 Oct 19;16(10):e0258858. doi: 10.1371/journal.pone.0258858. eCollection 2021.
6
Centralized registry for COVID-19 research recruitment: Design, development, implementation, and preliminary results.用于COVID-19研究招募的集中式登记系统:设计、开发、实施及初步结果。
J Clin Transl Sci. 2021 Jul 14;5(1):e152. doi: 10.1017/cts.2021.819. eCollection 2021.
7
Accelerated COVID-19 vaccine development: milestones, lessons, and prospects.加速 COVID-19 疫苗开发:里程碑、经验教训和前景。
Immunity. 2021 Aug 10;54(8):1636-1651. doi: 10.1016/j.immuni.2021.07.017. Epub 2021 Aug 3.
8
CTSA recruitment resources: An inventory of what CTSA hubs are currently offering.临床与转化科学奖(CTSA)招募资源:CTSA中心目前所提供资源的清单。
J Clin Transl Sci. 2020 May 12;4(6):529-536. doi: 10.1017/cts.2020.44.
9
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
10
HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform.HIV 感染与 COVID-19 死亡:基于人群的英国初级保健数据队列分析及 OpenSAFELY 平台内的全国死亡登记数据关联分析
Lancet HIV. 2021 Jan;8(1):e24-e32. doi: 10.1016/S2352-3018(20)30305-2. Epub 2020 Dec 11.